Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration. The review aims to provide an evidence-based update of clinical trials investigating the clinical efficacy, adverse-event profile, dosage and administration of this drug, alone or in combination with conventional chemotherapeutics and/or new target-oriented drugs, in the management colorectal cancer patients. (C) 2010 Elsevier Ltd. All rights reserved.
Update on capecitabine alone and in combination regimens in colorectal cancer patients / Silvestris, N., Maiello, E., De Vita, F., Cinieri, S., Santini, D., Russo, A., Tommasi, S., Azzariti, A., Numico, G., Pisconti, S., Petriella, D., Lorusso, V., Millaku, A., Colucci, G.. - In: CANCER TREATMENT REVIEWS. - ISSN 0305-7372. - 36:(2010), pp. S46-S55. [10.1016/S0305-7372(10)70020-7]
Update on capecitabine alone and in combination regimens in colorectal cancer patients
Santini D;
2010
Abstract
Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration. The review aims to provide an evidence-based update of clinical trials investigating the clinical efficacy, adverse-event profile, dosage and administration of this drug, alone or in combination with conventional chemotherapeutics and/or new target-oriented drugs, in the management colorectal cancer patients. (C) 2010 Elsevier Ltd. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
